# US 2021/0277450 A1 · Multiple amplification cycle detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277450 A1
- Document ID: US20210277450A1
- Status: Published application
- Kind: A1
- Application number: 17/329,844
- Filed: 2021-05-25
- Published: 2021-09-09
- Earliest claimed: 2012-09-10
- Assignees: BioFire Diagnostics, LLC
- Applicants: BioFire Diagnostics, LLC
- Inventors: Randy P. Rasmussen; Robert John Crisp; Andrew Clinton Hemmert; Elizabeth Barker Campbell; Thomas Charles Robbins; David J. Eyre
- Web page: https://patentgrep.com/patent/US20210277450A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6851: Quantitative amplification
- C12Q 1/689: for bacteria
- C12Q 1/705: {for herpetoviridae, e.g. herpes simplex, varicella zoster}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods and devices are provided for simultaneously amplifying a plurality of sample wells for a predetermined amount of amplification, detecting whether amplification has occurred in a first set of the wells, amplifying for an additional amount of amplification and detecting whether amplification has occurred in a second set of the wells. Methods are also provided for analyzing a target nucleic acid sequence using melt curves that were generated in a plurality of amplification cycles.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for analyzing a target nucleic acid in a sample comprising
(a) providing a sample container comprising a first sample well and a second sample well, the second sample well comprising therein primers for amplifying the target nucleic acid,
(b) subjecting the sample to a first amplification in the first sample well, and moving a portion of the sample from the first sample well to the second sample well,
(c) subjecting the second sample well to amplification conditions through a plurality of amplification cycles to amplify the target nucleic acid in the second sample well,
(d) generating a melt curve of the amplified target nucleic acid in the second sample well,
(e) repeating steps (c) and (d), and
(f) determining a Cp by identifying the amplification cycle in which a value for the melt curve exceeds a predetermined value,
wherein the sample in the second sample well contains two or more different target nucleic acids and the second sample well contains primers for amplifying the two or more different target nucleic acids, and the method further comprises:
simultaneously amplifying the two or more target nucleic acids in the second sample well through a plurality of amplification cycles,
generating a plurality of melt curves of the amplified two or more target nucleic acids,
determining a value for each of the plurality of melt curves from each of the amplified two or more target nucleic acids, and
determining a melt Cp for each of the two or more target nucleic acids by identifying a melt event in which the value for the melt curve for each of the two or more target nucleic acids exceeds a predetermined value.

### Claim 3 (depends on 2)

The method of claim 2, wherein the first amplification of step (b) is a multiplex amplification.

### Claim 4 (depends on 2)

The method of claim 2, wherein the value for the melt curve is determined by peak height or peak area of a negative derivative of the melt curve.

### Claim 5 (depends on 2)

The method of claim 2, further comprising generating the melt curve at every amplification cycle or nearly every amplification cycle.

### Claim 6 (depends on 2)

The method of claim 2, wherein the two or more target nucleic acids amplified in the second well are selected such that a melting temperature for the two or more target nucleic acids are sufficiently well separated from one another, so that melting of each one of the two or more target nucleic acids is discernable from melting of the others.

### Claim 7 (depends on 2)

The method of claim 2, wherein different amplification cycle numbers predetermined for each of the two or more target nucleic acids are used to distinguish between true positive and false positive detections.

### Claim 8 (depends on 2)

The method of claim 2, wherein different amplification cycle numbers predetermined for each of the two or more target nucleic acids are used to distinguish between clinically relevant infection, environmental contamination, or chromosomal integration.

### Claim 9

A method for analyzing a target nucleic acid in a sample comprising
(a) providing a sample container comprising a first sample well and a second sample well, the second sample well comprising therein primers for amplifying the target nucleic acid, a control nucleic acid, and primers for amplifying the control nucleic acid,
(b) subjecting the sample to a first amplification in the first sample well, and moving a portion of the sample from the first sample well to the second sample well,
(c) subjecting the sample well to amplification conditions through at least one amplification cycle to amplify the target nucleic acid and the control nucleic acid in the sample well, wherein the amplification conditions include a dsDNA binding dye,
(d) generating a melt curve of the amplified target nucleic acid and amplified control nucleic acid,
(e) determining a value for the amplified target nucleic acid, and
(f) repeating steps (c), (d), and (e).

### Claim 10 (depends on 9)

The method of claim 9, wherein the second sample well further comprises the dsDNA binding dye.

### Claim 11 (depends on 9)

The method of claim 9, wherein step (e) also includes determining a value for the amplified control nucleic acid.

### Claim 12 (depends on 11)

The method of claim 11, further comprising the step of generating a corrected amplification curve for the target nucleic acid using the values determined in step (e).

### Claim 13 (depends on 12)

The method of claim 12, wherein the melt curves are plotted as negative derivative melt curves, and the values are determined by peak height or peak area of a selected temperature window for each of the target and control nucleic acids.

### Claim 14 (depends on 13)

The method of claim 13, further comprising the step of determining a relative starting concentration of the target nucleic acid relative to a starting concentration of the control nucleic acid.

### Claim 15 (depends on 14)

The method of claim 14, wherein the relative starting concentration is determined using the formula
ET*Cp,t/EC*Cp,c
where
ET and EC are target and control efficiencies, and
Cp,t and Cp,c are target and control crossing points, determined by a cycle at which the value for the amplified template nucleic acid exceeds a predetermined value and at which the amplified control nucleic acid exceeds the predetermined value.

### Claim 16 (depends on 9)

The method of claim 9, further comprising the step of generating a corrected amplification curve for the control nucleic acid.

### Claim 17 (depends on 9)

The method of claim 9, further comprising generating the melt curve at every amplification cycle or nearly every amplification cycle.

### Claim 18 (depends on 9)

The method of claim 9, wherein sample container comprises a plurality of second sample wells for amplification of a plurality of target nucleic acids and wherein one or more of the plurality of second sample wells includes the control nucleic acid.

### Claim 19 (depends on 18)

The method of claim 18, wherein some of the plurality of sample wells include different control nucleic acids configured to be amplified with one or more of the plurality of target nucleic acids, and wherein the different control nucleic acids are selected such that their melting temperatures are separate and distinguishable from the melting temperatures of the one or more of the plurality of target nucleic acids.

### Claim 20 (depends on 10)

The method of claim 10, wherein different amplification cycle numbers predetermined for the target nucleic acid are used to distinguish between true positive and false positive detections.

### Claim 21 (depends on 10)

The method of claim 10, wherein different amplification cycle numbers predetermined for the target nucleic acid are used to distinguish between clinically relevant infection, environmental contamination, or chromosomal integration.
